A Phase 4 interventional study of Sodium Hyaluronate Ophthalmic 0.4% and Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15% in Photorefractive Keratectomy and Corneal De-epithelialization, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Laboratorios Sophia S.A de C.V. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Phase IV comparative, controlled, parallel group, open, randomized multicenter study to evaluate the efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo. Primary outcome measure is the time of corneal re-epithelialization after PRK surgery. Intervention includes administration of one of the experimental products quater per die (QID) for 14 days.
Laboratorios Sophia S.A de C.V. is the lead sponsor of 45 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnosis of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lagricel® Ofteno PF, multidose presentation (sodium hyaluronate 0.4%) Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
Drug: Sodium Hyaluronate Ophthalmic 0.4%
Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
Drug: Trehalose 3% / Sodium Hyaluronate Ophthalmic 0.15%
Topical ophthalmic administration of one drop of Lagricel® Ofteno PF QID.
Also known as: Lagricel® Ofteno PF, PRO-037
Drug page: Trehalose
Topical ophthalmic administration of one drop of Thealoz® Duo QID.
Also known as: Thealoz® Duo
Changes in Corneal Re-epithelialization (Time)
Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.
Time frame: Days: 1 (baseline visit), 2 (±1) (first follow-up visit), 3 (±1) (second follow-up visit), 7 (±1) (third follow-up visit)
Best Corrected Visual Acuity (BCVA)
(VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.
Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Changes in Ocular Comfort Index
Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.
Time frame: Days: 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Pain Perception
Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4)
Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Frequency of Pain Perception
Through a questionnaire, patients will be directly questioned about presence, severity and frequency of pain and associated symptoms. The scale will be as follows for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).
Time frame: Days: 1 (baseline visit: BV), 2 (±1) (first follow-up visit: V1), 3 (±1) (second follow-up visit: V2), 7 (±1) (third follow-up visit: V3) and 15 (±1) (final visit: FV)
Unexpected Adverse Events (AEs) Related to the Investigational Product
The number of unexpected adverse events related to the investigational product that were recorded in each treatment group is described
Time frame: Day: 17 (± 1) (safety call)
| Milestone | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| Started | 48 | 48 |
| Completed | 45 | 43 |
| Not completed | 3 | 5 |
| Withdrew: Protocol violation | 1 | 3 |
| Withdrew: Adherence below protocol-stipulated limit (70%) | 2 | 2 |
Corneal re-epithelialization will be evaluated through direct observation and photographic recording after application of fluorescein stain. After instillation of a drop of topical anesthetic (tetracaine 0.5%) a fluorescein strip will be applied on the inferior cul de sac while the patient looks upward. Using a slit lamp with magnification of 6x and 16x photographs (at least 6 images for each magnification) will be obtained.
| days | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| Changes in Corneal Re-epithelialization (Time) | 5.39 ± 3.78 | 5.34 ± 3.46 |
(VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome.
| decimal score | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| BV | 0.58 ± 0.16 | 0.61 ± 0.20 |
| V1 | 0.53 ± 0.16 | 0.55 ± 0.15 |
| V2 | 0.62 ± 0.18 | 0.65 ± 0.20 |
| V3 | 0.80 ± 0.18 | 0.76 ± 0.22 |
| FV | 0.88 ± 0.18 | 0.86 ± 0.19 |
Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.
| score on a scale | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| V3 | 25.20 ± 11.88 | 25.25 ± 11.36 |
| FV | 20.32 ± 11.78 | 19.51 ± 12.68 |
Through a questionnaire, patients will be directly questioned about presence and severity of pain and associated symptoms. The scale will be as follows for severity: absent (0), very mild (1), mild (2), moderate (3) and severe (4)
| Participants | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| BV Pain Perception — No pain | 3 | 3 |
| BV Pain Perception — Very mild pain | 4 | 7 |
| BV Pain Perception — Mild pain | 8 | 11 |
| BV Pain Perception — Moderate mild | 23 | 18 |
| BV Pain Perception — Severe pain | 7 | 4 |
| V1 Pain Perception — No pain | 7 | 6 |
| V1 Pain Perception — Very mild pain | 9 | 6 |
| V1 Pain Perception — Mild pain | 13 | 17 |
| V1 Pain Perception — Moderate mild | 15 | 12 |
| V1 Pain Perception — Severe pain | 1 | 2 |
| V2 Pain Perception — No pain | 23 | 21 |
| V2 Pain Perception — Very mild pain | 12 | 9 |
| V2 Pain Perception — Mild pain | 8 | 12 |
| V2 Pain Perception — Moderate mild | 1 | 0 |
| V2 Pain Perception — Severe pain | 1 | 1 |
| V3 Pain Perception — No pain | 38 | 36 |
| V3 Pain Perception — Very mild pain | 7 | 4 |
| V3 Pain Perception — Mild pain | 0 | 1 |
| V3 Pain Perception — Moderate mild | 0 | 2 |
| V3 Pain Perception — Severe pain | 0 | 0 |
| FV Pain Perception — No pain | 44 | 41 |
| FV Pain Perception — Very mild pain | 0 | 1 |
| FV Pain Perception — Mild pain | 1 | 0 |
| FV Pain Perception — Moderate mild | 0 | 1 |
| FV Pain Perception — Severe pain | 0 | 0 |
Through a questionnaire, patients will be directly questioned about presence, severity and frequency of pain and associated symptoms. The scale will be as follows for frequency: never (0), almost never (1), 50% of the time (2), almost all the time (3) and all the time (4).
| Participants | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| BV Frequency pain perception — At no time | 3 | 3 |
| BV Frequency pain perception — Almost never | 12 | 9 |
| BV Frequency pain perception — 50% of the time | 9 | 10 |
| BV Frequency pain perception — Almost all the time | 15 | 16 |
| BV Frequency pain perception — At all times | 6 | 5 |
| V1 Frequency pain perception — At no time | 7 | 6 |
| V1 Frequency pain perception — Almost never | 14 | 11 |
| V1 Frequency pain perception — 50% of the time | 15 | 16 |
| V1 Frequency pain perception — Almost all the time | 9 | 7 |
| V1 Frequency pain perception — At all times | 0 | 3 |
| V2 Frequency pain perception — At no time | 23 | 21 |
| V2 Frequency pain perception — Almost never | 18 | 17 |
| V2 Frequency pain perception — 50% of the time | 3 | 2 |
| V2 Frequency pain perception — Almost all the time | 1 | 1 |
| V2 Frequency pain perception — At all times | 0 | 2 |
| V3 Frequency pain perception — At no time | 38 | 36 |
| V3 Frequency pain perception — Almost never | 7 | 6 |
| V3 Frequency pain perception — 50% of the time | 0 | 0 |
| V3 Frequency pain perception — Almost all the time | 0 | 0 |
| V3 Frequency pain perception — At all times | 0 | 1 |
| FV Frequency pain perception — At no time | 44 | 41 |
| FV Frequency pain perception — Almost never | 1 | 1 |
| FV Frequency pain perception — 50% of the time | 0 | 0 |
| FV Frequency pain perception — Almost all the time | 0 | 0 |
| FV Frequency pain perception — At all times | 0 | 1 |
The number of unexpected adverse events related to the investigational product that were recorded in each treatment group is described
| number of events | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| expected related adverse events | 17 | 12 |
| Unexpected adverse events related to | 2 | 1 |
Collected over From day 1 (basal visit) to the safety call on day 17 (+1). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1; Lagricel® Ofteno PF | 0/48 (0%) | 0/48 (0%) | 39/48 (81.3%) |
| Group 2; Thealoz® Duo | 0/47 (0%) | 0/47 (0%) | 37/47 (78.7%) |
| Event | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo |
|---|---|---|
| Corneal epithelial defectEye disorders | 22/48 | 21/47 |
| Eye irritationEye disorders | 6/48 | 9/47 |
| Irritation in the instillation areaEye disorders | 9/48 | 5/47 |
| Foreign body sensation in the eyesEye disorders | 9/48 | 6/47 |
| Dry eyeEye disorders | 3/48 | 7/47 |
| Decreased visual acuityEye disorders | 4/48 | 5/47 |
| PhotophobiaEye disorders | 5/48 | 2/47 |
| Blurred visionEye disorders | 5/48 | 1/47 |
| Abnormal sensation in the eyeEye disorders | 4/48 | 1/47 |
| Eyelid edemaEye disorders | 2/48 | 3/47 |
| Age, Continuous(years) | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo | Total |
|---|---|---|---|
| Mean | 29.50 ± 7.01 | 26.74 ± 5.75 | 28.14 ± 6.53 |
| Sex: Female, Male(Participants) | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo | Total |
|---|---|---|---|
| Female | 32 | 29 | 61 |
| Male | 16 | 18 | 34 |
| Race/Ethnicity, Customized(Participants) | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo | Total |
|---|---|---|---|
| Hispanic or Latin | 48 | 47 | 95 |
| Not Hispanic or Latin | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo | Total |
|---|---|---|---|
| Mexico | 48 | 47 | 95 |
| Corneal epithelial defects(Participants) | Group 1; Lagricel® Ofteno PF | Group 2; Thealoz® Duo | Total |
|---|---|---|---|
| Count of participants | 22 | 21 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Dec 2023, 15 months.
Results were first posted in Apr 2026, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratorios Sophia S.A de C.V. →